-Yasuo Morishima Researcher Activity Profile

Research Author Detailed Information 

Yasuo Morishima Publication Rate By Year

Yasuo Morishima has published 13 paper(s) in 2007, for a total of 13 research publications in total.

Yasuo Y Morishima Author Information

LAST NAME: morishima

FIRST NAME: yasuo

INITIALS: Y

AFFILIATION:

Papers

Yasuo Morishima's Publication Record

1. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Year Published: 2007
Department of HSCT Data Management, Nagoya University, School of Medicine, Nagoya, Japan.
2. Primary hepatic follicular lymphoma : a case report and discussion of chemotherapy and favorable outcomes. Year Published: 2007
Department of Hematology and Cell Therapy, Aichi Cancer Center.
3. [The unification of hematopoietic stem cell transplantation registry in Japan and establishment of the TRUMP system] Year Published: 2007
Department of HSCT Data Management, Nagoya University, School of Medicine.
4. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Year Published: 2007
Department of Hematology and Oncology, Tokai University School of Medicine, 143, Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. yoshioga@is.icc.u-tokai.ac.jp
5. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Year Published: 2007
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681, Japan.
6. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Year Published: 2007
Department of HSCT Data Management, Nagoya University, School of Medicine, Nagoya, Japan.
7. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Year Published: 2007
Japanese Red Cross Tokyo Metropolitan Blood Center, Tokyo, Japan. to-yabe@tokyo.bc.jrc.or.jp
8. Primary hepatic follicular lymphoma : a case report and discussion of chemotherapy and favorable outcomes. Year Published: 2007
Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
9. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Year Published: 2007
Japanese Red Cross Tokyo Metropolitan Blood Center, Tokyo, Japan. to-yabe@tokyo.bc.jrc.or.jp
10. Primary hepatic follicular lymphoma : a case report and discussion of chemotherapy and favorable outcomes. Year Published: 2007
Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
11. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Year Published: 2007
Department of Hematology and Oncology, Tokai University School of Medicine, 143, Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. yoshioga@is.icc.u-tokai.ac.jp
12. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Year Published: 2007
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681, Japan.
13. [The unification of hematopoietic stem cell transplantation registry in Japan and establishment of the TRUMP system] Year Published: 2007
Department of HSCT Data Management, Nagoya University, School of Medicine.